A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease
Latest Information Update: 05 Aug 2025
At a glance
- Drugs Astegolimab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms ALIENTO
- Sponsors Genentech
Most Recent Events
- 21 Jul 2025 Results published in a Roche media release
- 21 Jul 2025 Results presented in a Roche media release.
- 20 Jul 2025 According to Genentech media release, analysis of the study data will be discussed with regulatory authorities and shared at an upcoming medical meeting.